Cargando…
Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
The impact of age on the clinical benefit of anti-PD1 immunotherapy in advanced melanoma patients has been evolving recently. Due to a reduced immune function in elderly patients, young patients with a robust immune system are theoretically expected to benefit more from the treatment approach. Howev...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707626/ https://www.ncbi.nlm.nih.gov/pubmed/34947849 http://dx.doi.org/10.3390/life11121318 |
_version_ | 1784622482186043392 |
---|---|
author | Machiraju, Devayani Schäfer, Sarah Hassel, Jessica C. |
author_facet | Machiraju, Devayani Schäfer, Sarah Hassel, Jessica C. |
author_sort | Machiraju, Devayani |
collection | PubMed |
description | The impact of age on the clinical benefit of anti-PD1 immunotherapy in advanced melanoma patients has been evolving recently. Due to a reduced immune function in elderly patients, young patients with a robust immune system are theoretically expected to benefit more from the treatment approach. However, in contrast to this hypothesis, recent studies in patients with metastatic melanoma have demonstrated that immunotherapy, especially with anti-PD1 treatment, is less effective in patients below 65 years, on average, with significantly lower responses and reduced overall survival compared to patients above 65 years of age. Besides, data on young patients are even more sparse. Hence, in this review, we will focus on age-dependent differences in the previously described resistance mechanisms to the treatment and discuss the development of potential combination treatment strategies for enhancing the anti-tumor efficacy of anti-PD1 or PDL1 treatment in young melanoma patients. |
format | Online Article Text |
id | pubmed-8707626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87076262021-12-25 Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma Machiraju, Devayani Schäfer, Sarah Hassel, Jessica C. Life (Basel) Review The impact of age on the clinical benefit of anti-PD1 immunotherapy in advanced melanoma patients has been evolving recently. Due to a reduced immune function in elderly patients, young patients with a robust immune system are theoretically expected to benefit more from the treatment approach. However, in contrast to this hypothesis, recent studies in patients with metastatic melanoma have demonstrated that immunotherapy, especially with anti-PD1 treatment, is less effective in patients below 65 years, on average, with significantly lower responses and reduced overall survival compared to patients above 65 years of age. Besides, data on young patients are even more sparse. Hence, in this review, we will focus on age-dependent differences in the previously described resistance mechanisms to the treatment and discuss the development of potential combination treatment strategies for enhancing the anti-tumor efficacy of anti-PD1 or PDL1 treatment in young melanoma patients. MDPI 2021-11-30 /pmc/articles/PMC8707626/ /pubmed/34947849 http://dx.doi.org/10.3390/life11121318 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Machiraju, Devayani Schäfer, Sarah Hassel, Jessica C. Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma |
title | Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma |
title_full | Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma |
title_fullStr | Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma |
title_full_unstemmed | Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma |
title_short | Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma |
title_sort | potential reasons for unresponsiveness to anti-pd1 immunotherapy in young patients with advanced melanoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707626/ https://www.ncbi.nlm.nih.gov/pubmed/34947849 http://dx.doi.org/10.3390/life11121318 |
work_keys_str_mv | AT machirajudevayani potentialreasonsforunresponsivenesstoantipd1immunotherapyinyoungpatientswithadvancedmelanoma AT schafersarah potentialreasonsforunresponsivenesstoantipd1immunotherapyinyoungpatientswithadvancedmelanoma AT hasseljessicac potentialreasonsforunresponsivenesstoantipd1immunotherapyinyoungpatientswithadvancedmelanoma |